This interventional trial (n=27), led by Maastricht University with sponsorship from the Department of Psychology and Neurosciences, involves exploring the dose-response relationship in LSD-induced subjective and cognitive effects in healthy volunteers.
The study, focusing on LSD microdosing, aims to characterise the effects of small doses (5, 10, and 20 µg) compared to a placebo. The hypothesis is that higher doses of LSD will be associated with greater and potentially qualitatively different subjective effects.
The secondary objective includes assessing changes in cognitive performance. The study duration is one year, and the intervention involves administering placebo and LSD doses. Eligible participants, aged 18-40, with previous psychedelic experience, will be enrolled in a crossover, double-blinded, randomised controlled trial. The trial, initiated on May 1, 2018, is pending recruitment completion with 27 anticipated participants.
Trial Details
Trial Number
Sponsors & Collaborators
Maastricht UniversityMaastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.
Papers
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled TrialThis qualitative study (n=40) of healthy males following a double-blind placebo-controlled trial of LSD microdosing (10µg every third day for 6 weeks) found participants reported effects across emotions and mood, social life, mindfulness, cognition and creativity, and physiological domains, with key themes including openness to experiences and bidirectionality of effects, alongside reports of changes in anxiety suggesting important considerations for patient selection and dose optimisation.